Study on the Safety and Effectiveness of a Biodegradable Patent Foramen Ovale Occluder System
NCT ID: NCT07300358
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
258 participants
INTERVENTIONAL
2025-12-30
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardi-o-fix PFO occluder
Participants treated with th with the Cardi-o-fix PFO occluder according to the INSTRUCTIONS for Use (IFU)
Active Comparator
Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
Biodegradable PFO occluder system
Participants treated with th with the biodegradable PFO occluder system according to the INSTRUCTIONS for Use (IFU)
Experimental
Transcatheter closure of a patent foramen ovale (PFO) with biodegradable PFO occluder
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active Comparator
Percutaneously occlusion of PFO with Cardi-o-fix PFO occluder
Experimental
Transcatheter closure of a patent foramen ovale (PFO) with biodegradable PFO occluder
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Presence of a patent foramen ovale (PFO) confirmed by transthoracic echocardiography (TTE) or transesophageal echocardiography (TEE).
* Presence of a moderate-to-large right-to-left shunt (RLS) at rest or during the Valsalva maneuver, as confirmed by agitated saline contrast echocardiography (also known as bubble study).
* Clinically diagnosed with a PFO-associated ischemic stroke or transient ischemic attack (TIA).
Exclusion Criteria
* Large territory cerebral infarction within 4 weeks prior to the planned procedure.
* Atherosclerotic stenosis (\>50%) of the carotid or vertebral arteries, as confirmed by CT angiography or vascular ultrasound per investigator assessment.
* Presence of intracardiac thrombus or vegetation as confirmed by echocardiography.
* Left ventricular ejection fraction (LVEF) \< 35%.
* Atrial fibrillation or atrial flutter.
* Left ventricular aneurysm or severe regional wall motion abnormality.
* Significant valvular stenosis or regurgitation, or history of valvular replacement or repair surgery.
* Pulmonary hypertension or a PFO constituting a special conduit (e.g., right-to-left shunt due to elevated right heart pressures).
* Other confirmed causes of right-to-left shunt, such as atrial septal defect (ASD) or pulmonary arteriovenous fistula.
* Complex PFO anatomy (e.g., multi-tunnel PFO) or PFO associated with an ASD requiring different closure strategy.
* Thrombus, mass, or vegetation identified at the intended implant site or along the potential delivery pathway.
* Acute myocardial infarction or unstable angina within 3 months prior to the procedure.
* Previous implantation of an inferior vena cava filter, PFO closure device, or ASD closure device.
* Any other condition deemed by the investigator to make the patient unsuitable for PFO device implantation.
* Concomitant cardiac anomalies requiring surgical correction.
* Uncontrolled systemic or local infection, or sepsis.
* Active infection requiring concurrent antibiotic therapy (Patients with transient conditions may be enrolled after completing antibiotic therapy and a subsequent 14-day washout period).
* Contraindication to antiplatelet or anticoagulant therapy (e.g., major bleeding within 3 months, known retinopathy, history of intracranial hemorrhage, or other significant intracranial pathology).
* Known hypersensitivity or allergy to tantalum or nickel.
* Pregnancy, lactation, or women of childbearing potential not using highly effective contraception.
* Life expectancy less than 1 year due to malignancy or other comorbid disease.
* Current participation in another investigational drug or device clinical study that has not yet completed its primary endpoint.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Lingsi Medical Technology Co., Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
XiangBin Pan, Doctor
Role: PRINCIPAL_INVESTIGATOR
Chinese Academy of Medical Sciences, Fuwai Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Wenbin Ouyang, Doctor
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ShanghaiLingsiMedTech
Identifier Type: -
Identifier Source: org_study_id